Medtronic plc (MDT) Enterprise Value (EV): $106.80B
The enterprise value (EV) for Medtronic plc (MDT) is $106.80B as of Wednesday, June 10, 2026.
MDT Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$106.80B
MDT Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Medtronic plc (MDT) | — | $106.80B |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | $114.72B |
| Bristol-Myers Squibb Company (BMY) | $114.14B | $147.02B |
| Elevance Health Inc. (ELV) | $87.43B | $101.50B |
| CVS Health Corporation (CVS) | $125.16B | $185.63B |
| Cigna Corporation (CI) | $78.25B | $96.98B |
| Danaher Corporation (DHR) | $130.25B | $175.72B |
| Regeneron Pharmaceuticals, Inc. (REGN) | $62.59B | $80.33B |
| Pfizer Inc. (PFE) | $146.36B | $207.77B |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | $199.07B |
Enterprise Value Calculation
Market Cap
$103.04B
Total Debt
$28.46B
Cash
$2.22B
Enterprise Value
$106.80B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Medtronic plc Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medtronic plc Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Medtronic plc (MDT)?
- The enterprise value (EV) for MDT stock is $106.80B.
Related Metrics
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha